Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 420
- Registration Number
- NCT00307749
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2013-01-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 401
- Registration Number
- NCT00200356
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: Ursodeoxycholic acid 150mg / dayDrug: Ursodeoxycholic acid 600mg / dayDrug: Ursodeoxycholic acid 900mg / day
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 596
- Registration Number
- NCT00200343
- Locations
- π―π΅
Department of Gastroenterology, University of Tokyo, hongo, bunkyo-ku, Tokyo, Japan
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT00147316
- Locations
- π―π΅
National Cardiovascular Center, Suita, Osaka, Japan
Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT00147303
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2008-08-19
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 1510
- Registration Number
- NCT00129805
MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients
Phase 2
Completed
- Conditions
- Myocardial Infarction
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 414
- Registration Number
- NCT00078013
- Locations
- πΊπΈ
Massachusetts General Hospital/ Harvard Medical School, Boston, Massachusetts, United States
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Phase 3
Terminated
- Conditions
- Peripheral Vascular Disease
- First Posted Date
- 2003-05-02
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 560
- Registration Number
- NCT00059644
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Phase 3
Completed
- Conditions
- Peripheral Vascular Disease
- First Posted Date
- 2003-05-02
- Last Posted Date
- 2006-05-19
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 280
- Registration Number
- NCT00059657
Β© Copyright 2025. All Rights Reserved by MedPath